The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.

ABSTRACT:

Background

The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits. Currently, molecular targeting agents and late-line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available. However, the impact of this increase in drug availability on overall survival (OS) in mCRC remains a clinical question.

Methods

We retrospectively collected data on consecutive mCRC patients who were treated at three institutions in Japan. We divided the patients into three cohorts: patients who initiated first-line treatment from Jan 2005 to Dec 2006 (cohort A: only cytotoxic drugs available), Jan 2007 to Dec 2011 (cohort B: molecular targeting drugs available), and Jan 2012 to Sep

SUBMITTER: Kawakami T 

PROVIDER: S-EPMC9160807 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature